Leerink Partnrs Brokers Reduce Earnings Estimates for DexCom

DexCom, Inc. (NASDAQ:DXCM) – Equities research analysts at Leerink Partnrs lowered their FY2025 EPS estimates for shares of DexCom in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the medical device company will post earnings per share of $2.06 for the year, down from their prior forecast of $2.07. The consensus estimate for DexCom’s current full-year earnings is $1.71 per share. Leerink Partnrs also issued estimates for DexCom’s Q4 2025 earnings at $0.66 EPS.

A number of other research analysts have also recently weighed in on DXCM. Stifel Nicolaus raised their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. Royal Bank of Canada dropped their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Wells Fargo & Company lifted their target price on shares of DexCom from $80.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Finally, Raymond James lowered their target price on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research note on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Trading Up 0.2 %

Shares of DXCM opened at $78.10 on Wednesday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm has a 50 day simple moving average of $71.11 and a 200-day simple moving average of $88.51. DexCom has a 1-year low of $62.34 and a 1-year high of $142.00. The stock has a market cap of $30.51 billion, a price-to-earnings ratio of 46.77, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17.

Insider Activity

In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock valued at $399,319 in the last ninety days. Company insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

Several hedge funds and other institutional investors have recently made changes to their positions in DXCM. Kennedy Capital Management LLC acquired a new position in shares of DexCom during the 1st quarter valued at $1,690,000. B. Riley Wealth Advisors Inc. lifted its holdings in DexCom by 132.0% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 3,766 shares of the medical device company’s stock worth $522,000 after buying an additional 2,143 shares in the last quarter. Tidal Investments LLC lifted its holdings in DexCom by 151.8% in the 1st quarter. Tidal Investments LLC now owns 37,439 shares of the medical device company’s stock worth $5,193,000 after buying an additional 22,572 shares in the last quarter. iA Global Asset Management Inc. lifted its holdings in DexCom by 2.1% in the 1st quarter. iA Global Asset Management Inc. now owns 81,003 shares of the medical device company’s stock worth $11,235,000 after buying an additional 1,694 shares in the last quarter. Finally, Plato Investment Management Ltd lifted its holdings in DexCom by 469.4% in the 1st quarter. Plato Investment Management Ltd now owns 13,763 shares of the medical device company’s stock worth $1,909,000 after buying an additional 11,346 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.